Sterling Pharma Solutions

Sterling Pharma Solutions and Kivu Bioscience Enter Manufacturing Pact

Sterling Pharma Solutions to produce an antibody-drug conjugate (ADC) candidate for Kivu Bioscience.

Sterling Pharma Solutions Expands GMP ADC Manufacturing Capacity

Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million (€11.9 million) investment to increase GMP bioconjugation capacity.

Expert Statement: Chad Telgenhof, Sterling Pharma Solutions

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Sterling Expands HPAPI Capabilities at US Facility

UK-headquartered contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has invested $3 million at its US facility in Germantown, WI, to expand the company’s integrated antibody-drug conjugate (ADC) development and manufacturing capabilities.

A New Standard of Collaboration for the Pharmaceutical Industry

Headquartered in Cramlington, UK, Sterling Pharma Solutions is a contract development and manufacturing organization (CDMO) that provides a range of services to the global biopharmaceutical industry, including active pharmaceutical ingredient (API) development, scale-up and cGMP manufacturing, as well as antibody drug conjugate (ADC) R&D and clinical-scale GMP manufacturing.

Sterling Pharma Solutions Acquires UK CRO NewChem Technologies

Sterling Pharma Solutions has completed the acquisition of UK-based NewChem Technologies, a contract services provider focused on organic chemistry and supplying customers across a range of industries from pharmaceuticals, diagnostics and biotechnology, to veterinary science and chemicals.

Flow Chemistry

Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.

Flow Chemistry

Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.

Sterling Pharma Solutions Expands UK ADC facility

CDMO Sterling Pharma Solutions has announced plans to invest £1 million in an expansion of its site at Deeside, UK, which is dedicated to bioconjugation and antibody-drug conjugates (ADCs). The move follows its acquisition of the site’s owner ADC Biotechnology in April last year.

Expert Interview: Andrew Henderson, Sterling Pharma Solutions

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

GHO Capital Buys Sterling Pharma Solutions